Poised epigenetic states and acquired drug resistance in cancer

Cited by (303)

Items 101–200 of 303

1. Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer
   Arturo Álvarez-Arenas, Ana Podolski-Renić, Juan Belmonte-Beitia, Milica Pešić, Gabriel F. Calvo · 2019 · Scientific Reports
2. Metabolic Signaling to Epigenetic Alterations in Cancer
   Jung‐Ae Kim, Young Il Yeom · 2017 · Biomolecules & Therapeutics
3. New tools for old drugs: Functional genetic screens to optimize current chemotherapy
   Nora M. Gerhards, Sven Rottenberg · 2018 · Drug Resistance Updates
4. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma
   Manish V. Bais · 2019 · Journal of Dental Research
5. Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia
   Rong Deng, Bai Ji, Hongliang Yu, Wei Bao, Zhuoqi Yang, Ying Fang Yu, Yahan Cui, Yangyang Du, Meiyu Song, Shujun Liu et al. · 2019 · Scientific Reports
6. Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
   Asmaa El-Kenawi, Anders Berglund, Veronica C. Estrella, Yonghong Zhang, Min Liu, Ryan M. Putney, Sean Yoder, Joseph Johnson, Joel S. Brown, Robert A. Gatenby · 2022 · Cancer Research
7. Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerations
   Christoph Oing, Margaretha A. Skowron, Carsten Bokemeyer, Daniel Nettersheim · 2019 · Andrology
8. Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
   Suleyman Vural, Alida Palmisano, William C. Reinhold, Yves G. Pommier, Beverly A. Teicher, Julia Krushkal · 2021 · Clinical Epigenetics
9. The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
   Shaun Wood, Amber R. Willbanks, Jason Xiaojun Cheng · 2021 · Current Cancer Drug Targets
10. The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
    Chiara Bellio, Celeste M. DiGloria, David R. Spriggs, Rosemary Foster, Whitfield B. Growdon, Bo R. Rueda · 2019 · Cancers
11. Episensitization: Defying Time’s Arrow
    Bryan T. Oronsky, Arnold L. Oronsky, Michelle Lybeck, Neil C. Oronsky, Jan J. Scicinski, Corey Allan Carter, Regina M. Day, José F. Rodríguez‐Orengo, Maribel Rodriguez‐Torres, Gary R. Fanger et al. · 2015 · Frontiers in Oncology
12. Capturing and Understanding the Dynamics and Heterogeneity of Gene Expression in the Living Cell
    Amparo Pascual‐Ahuir, Josep Fita‐Torró, Markus Proft · 2020 · International Journal of Molecular Sciences
13. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations
    Niraj Kumar, Gwendolyn M. Cramer, Seyed Alireza Zamani-Dahaj, Bala Sundaram, Jonathan P. Celli, Rahul Kulkarni · 2019 · Scientific Reports
14. Discrete and continuum phenotype-structured models for the evolution of cancer cell populations under chemotherapy
    Rebecca E.A. Stace, Thomas Stiehl, Mark A. J. Chaplain, Anna K. Marciniak-Czochra, Tommaso Lorenzi · 2020 · Mathematical Modelling of Natural Phenomena
15. Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology
    Robert Klopfleisch, Barbara Kohn, Achim Dieter Gruber · 2015 · The Veterinary Journal
16. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation
    Tahiyat Alothaim, Morgan Charbonneau, Xiaohu Tang · 2021 · Scientific Reports
17. Prediction of therapy response in ovarian cancer: Where are we now?
    Khalid El Bairi, M. Amrani, Abdul Hafeez Kandhro, Saïd Afqir · 2017 · Critical Reviews in Clinical Laboratory Sciences
18. Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response
    Zhi Yang, Feifei S. Xue, Minhuan Li, Xingya Zhu, Xiaofeng Lu, Chao Wang, En Xu, Xingzhou Wang, Liang Zhang, Yu Heng et al. · 2021 · Frontiers in Oncology
19. m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance
    Chen Chen, Yuying Guo, Yaxin Guo, Xiaoke Wu, Chaohua Si, Yanxin Xu, Qiaozhen Kang, Zhenqiang Sun · 2021 · Frontiers in Oncology
20. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1
    Jeeho Kim, In Youb Chang, Ho Jin You · 2022 · Cell Death and Disease
21. Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
    Rebecca A. Jackson, Ee Sin Chen · 2016 · Pharmacology & Therapeutics
22. Construction and applications of DNA-based nanomaterials in cancer therapy
    Hedong Qi, Yuwei Xu, Pin Hu, Chi Yao, Dayong Yang · 2021 · Chinese Chemical Letters
23. MDR1 mediated chemoresistance: BMI1 and TIP60 in action
    Soumyajit Banerjee Mustafi, Prabir Kumar Chakraborty, Sarwat Naz, Shailendra Kumar Dhar Dwivedi, Mark Street, Rumki Basak, Da Yang, Kai Ding, Priyabrata Mukherjee, Resham Bhattacharya · 2016 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
24. Epigenome-wide association studies for cancer biomarker discovery in circulating cell-free DNA: technical advances and challenges
    Miljana Tanić, Stephan Beck · 2017 · Current Opinion in Genetics & Development
25. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression
    Marina Natoli, John Gallon, Haonan Lu, Ala Amgheib, David James Pinato, Francesco Angelo Mauri, Teresa Marafioti, Ayse U. Akarca, Ines Ullmo, Jacey Ip et al. · 2021 · Journal for ImmunoTherapy of Cancer
26. miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
    Kha Wai Hon, Nadiah Abu, Nurul‐Syakima Ab Mutalib, Rahman A Jamal · 2018 · Frontiers in Pharmacology
27. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
    Chuntao Quan, Yuchen Chen, Xiaomu Wang, Dong Liang Yang, Qing Wang, Yixue Huang, Robert B. Petersen, Xinran Liu, Ling Zheng, Yangkai Li et al. · 2020 · Cancer Letters
28. Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin β3/SRC pathway
    Wenyi Zhang, Rulu Pan, Mei Lu, Qian Zhang, Ziqi Lin, Yuan Qin, Zhanyu Wang, Siqing Gong, Huan Lin, Shuyi Chong et al. · 2021 · Oncogene
29. A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy
    Yongjiang Zheng, Jiguang Bao, Qiyi Zhao, Tianshou Zhou, Xiaoqiang Sun · 2018 · Molecular Cancer Therapeutics
30. Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer
    Ryan A. Hlady, Keith D. Robertson · 2018 · Seminars in Liver Disease
31. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance
    Maolin Ge, Zhi Qiao, Yan Kong, Hongyu Liang, Yan Sun, Hui Juan Lu, Zhenshu Xu, Han Liu · 2020 · British Journal of Cancer
32. Cancer genes and cancer stem cells in tumorigenesis: Evolutionary deep homology and controversies
    Vladimir Florin Niculescu · 2022 · Genes & Diseases
33. Applications of Nanopore sequencing in precision cancer medicine
    Sergey A. Dyshlovoy, Stefanie Paigin, Ann‐Kristin Afflerbach, Annabelle Lobermeyer, Stefan Werner, Ulrich Schüller, Carsten Bokemeyer, Anna Schuh, Lina Bergmann, Gunhild v. Amsberg et al. · 2024 · International Journal of Cancer
34. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer
    Jian Zhang, Kejia Zhao, Wenjing Zhou, Ran Kang, Shiyou Wei, Yueli Shu, Yu Cheng, Yin Ku, Yonghong Mao, Hao Luo et al. · 2024 · Signal Transduction and Targeted Therapy
35. In Silico Investigations of Multi-Drug Adaptive Therapy Protocols
    Daniel S. Thomas, Luis Humberto Cisneros, Alexander R.A. Anderson, Carlo C. Maley · 2022 · Cancers
36. Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
    Meixia Chen, Jing Nie, Yang Liu, Xiang Li, Yan Zhang, Malcolm V. Brock, Kaichao Feng, Zhiqiang Wu, Xiaolei Li, Lu Shi et al. · 2018 · International Journal of Cancer
37. NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer
    Hsin-Hua Chung, Chun‐Te Lee, Je‐Ming Hu, Yu‐Ching Chou, Ya‐Wen Lin, Yu‐Lueng Shih · 2020 · International Journal of Molecular Sciences
38. Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
    Maolin Ge, Zhi Qiao, Yan Kong, Hui Juan Lu, Han Liu · 2020 · Cancer Science
39. New Insights into Therapy-Induced Progression of Cancer
    Polina V. Shnaider, Olga M. Ivanova, Irina K. Malyants, Ksenia S. Anufrieva, Ilya A. Semenov, Marat S. Pavlyukov, Maria A. Lagarkova, Vadim Markovich Govorun, Victoria О. Shender · 2020 · International Journal of Molecular Sciences
40. Managing Cancer Drug Resistance from the Perspective of Inflammation
    Shuaijun Lu, Yang Li, Changling Zhu, Weihua Wang, Yuping Zhou · 2022 · Journal of Oncology
41. Pan-cancer landscape of epigenetic factor expression predicts tumor outcome
    Michael W. Cheng, Mithun Mitra, Hilary A. Coller · 2023 · Communications Biology
42. Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis
    Chie Kikutake, Koji Yahara · 2016 · PLoS ONE
43. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
    Ana J. Rodrigues Moita, Jan Josef Bandolik, Finn K. Hansen, Thomas Kurz, Alexandra Hamacher, Matthias Ulrich Kassack · 2020 · International Journal of Molecular Sciences
44. Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment
    Julia Krushkal, Yingdong Zhao, Curtis D. Hose, Anne P. Monks, James H. Doroshow, Richard Simon · 2016 · Clinical Epigenetics
45. Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
    Rajita J. Vatapalli, Alex P. Rossi, Ho Man Chan, Jingwen Zhang · 2024 · Epigenomics
46. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function
    Dawei Wang, Dong You, Lei Li · 2019 · The Journal of Toxicological Sciences
47. Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
    Sheng‐Fang Su, Chia-Hsin Liu, Chiou-Ling Cheng, Chao‐Chi Ho, Tsung‐Ying Yang, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Huei‐Wen Chen, Gee‐Chen Chang et al. · 2021 · JCO Precision Oncology
48. Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
    Chandru Gajendran, Subramanyam Janardhan Tantry, Naveen Sadhu M, Mohammed Zainuddin, Purushottam M. Dewang, Mahanandeesha Siddappa Hallur, Sreekala Nair, Krishnakumar Vaithilingam, Basavaprabhu Nagayya, Sridharan Rajagopal et al. · 2023 · PLoS ONE
49. Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment
    Xiaochao Huang, Yuanhang Chen, Wentian Zhong, Zhikun Liu, Haijiang Zhang, Bin Zhang, Heng‐Shan Wang · 2022 · European Journal of Medicinal Chemistry
50. Novel chemokine-like activities of histones in tumor metastasis
    Ruochan Chen, Yangchun Xie, Xiao Yan Zhong, Yongmin Fu, Yan Huang, Yixiang Zhen, Pinhua Pan, Haichao Wang, David L. Bartlett, Timothy R. Billiar et al. · 2016 · Oncotarget
51. Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies
    Audrey Vincent, Aïcha Ouelkdite, Mouloud Souidi, Julie Leclerc, Bernadette Neve, Isabelle VAN SEUNINGEN · 2019 · World Journal of Stem Cells
52. Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer
    Kiyoshi Misawa, Masato Mima, Satoshi Yamada, Yuki Misawa, Atsushi Imai, Daiki Mochizuki, Takuya Nakagawa, Tomoya Kurokawa, Miki Oguro, Ryuji Ishikawa et al. · 2020 · Scientific Reports
53. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
    Michał Marczyk, Gauri Anand Patwardhan, Jun Zhao, Rihao Qu, Xiaotong Li, Vikram B. Wali, Abhishek Kumar Gupta, Manoj M. Pillai, Yuval Kluger, Qin Yan et al. · 2020 · Cancers
54. Critical role of HMGA proteins in cancer cell chemoresistance
    Daniela D’Angelo, Paula Müssnich, Claudio Arra, Sabrina Battista, Alfredo Fusco · 2017 · Journal of Molecular Medicine
55. Epigenetic Mechanisms in Canine Cancer
    Pedro Luiz Porfírio Xavier, Susanne Müller, Heidge Fukumasu · 2020 · Frontiers in Oncology
56. G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells
    Jenna Robinson, Gem Flint, Ian Garner, Silvia Galli, Thomas E. Maher, Marina K. Kuimova, Ramón Vilar, Iain A. McNeish, Robert Eldon Brown, Hector C. Keun et al. · 2025 · Genome biology
57. Translocation of intracellular CD24 constitutes a triggering event for drug resistance in breast cancer
    Hugo Werner Huth, Thiago Castro‐Gomes, Alfredo Miranda Goes, Catherine Ropert · 2021 · Scientific Reports
58. Combinatorial perturbation sequencing on single cells using microwell-based droplet random pairing
    Run Xie, Yang Liu, Shiyu Wang, Xuyang Shi, Zhantao Zhao, Ya Liu, Zida Li, Zida Li · 2022 · Biosensors and Bioelectronics
59. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells
    Sivakumar Vijayaraghavalu, Vinod D. Labhasetwar · 2018 · Drug Delivery and Translational Research
60. Chromatin Structure and Drug Resistance in Candida spp.
    Callum J. O’Kane, Rachel Weild, Edel M. Hyland · 2020 · Journal of Fungi
61. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance
    John Gallon, Erick W. Loomis, Edward WJ Curry, Nicholas G. Martin, Leigh Brody, Ian Garner, Robert Eldon Brown, James M. Flanagan · 2021 · Clinical Epigenetics
62. Comprehensive characterization of a drug-resistance-related ceRNA network across 15 anti-cancer drug categories
    Bing Liu, Xiaorui Zhou, Dongyuan Wu, Xuesong Zhang, Xiuyun Shen, Kai Mi, Zhangyi Qu, Yanan Jiang, Desi Shang · 2021 · Molecular Therapy — Nucleic Acids
63. A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
    Olga Lancho, Amartya Singh, Victoria da Silva-Diz, Luca Tottone, Patrícia Renck Nunes, Maya Aleksandrova, Jesminara Khatun, Shirley Luo, Caifeng Zhao, Haiyan Zheng et al. · 2022 · Blood Cancer Discovery
64. Bifurcation analysis for a fractional‐order chemotherapy model with two different delays
    Changjin Xu, Peiluan Li, Maoxin Liao, Shuai Yuan · 2019 · Mathematical Methods in the Applied Sciences
65. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
    Tingting Lin, Wei Xiong, Guihua Chen, Yang He, Long Li, Xinfu Gao, Jialin Zhou, Wen-wen Lv, Yongzhuo Huang · 2023 · Acta Pharmacologica Sinica
66. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
    Anand Kamal Singh, Nishi Chandra, Sharmila A. Bapat · 2015 · Clinical Cancer Research
67. Synthesis and biological evaluation of novel millepachine derivative containing aminophosphonate ester species as novel anti-tubulin agents
    Xiaochao Huang, Meng Wang, Chun‐Gu Wang, Weiwei Hu, Qinghong You, Tianhua Ma, Qiang Jia, Chunhao Yu, Zhi‐Xin Liao, Heng‐Shan Wang · 2019 · Bioorganic Chemistry
68. Key genes and drug delivery systems to improve the efficiency of chemotherapy
    Zally Torres‐Martínez, Yamixa Delgado, Yancy Ferrer‐Acosta, Ivette J. Suárez-Arroyo, Freisa M. Joaquín-Ovalle, Louis Jean Delinois, Kai H. Griebenow · 2020 · Cancer Drug Resistance
69. Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
    Mijin Park, Byul Moon, Jong-Hwan Kim, Seung‐Jin Park, Seon‐Young Kim, Kihyun Park, Jaehoon Kim, Seon‐Young Kim, Jeong‐Hoon Kim, Jung‐Ae Kim · 2022 · Molecules and Cells
70. Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
    Ian Garner, Robert Eldon Brown · 2022 · Cancers
71. Statistical inference of the rates of cell proliferation and phenotypic switching in cancer
    Einar Bjarki Gunnarsson, Jasmine Foo, Kevin Leder · 2022 · Journal of Theoretical Biology
72. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis
    Reema Baskar, Harris G. Fienberg, Zumana Khair, Patricia M.B. Favaro, Samuel C. Kimmey, Douglas R. Green, Garry P. Nolan, Sylvia K. Plevritis, Sean C. Bendall · 2019 · Life Science Alliance
73. Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
    Ramiro Vázquez, Gianluca Civenni, Aleksandra Kokanovic, Dheeraj A. Shinde, Jasmine Cantergiani, Martina Marchetti, Giada Zoppi, Bruce Ruggeri, Phillip C.C. Liu, Giuseppina Maria Carbone et al. · 2019 · European Urology Oncology
74. Simultaneous profiling of RNA isoforms and chromatin accessibility of single cells of human retinal organoids
    Shuyao Zhang, Yuhua Xiao, Xinzhi Mo, Xu Chen, Jiawei Zhong, Zheyao Chen, Xu Liu, Yuanhui Qiu, Wangxuan Dai, Jia Chen et al. · 2024 · Nature Communications
75. Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment
    Shiv Poojan, Seung-Hyun Bae, Jae-Woong Min, Eun Young Lee, Yura Song, Hee Yeon Kim, Hye Won Sim, Eun‐Kyung Kang, Young-Ho Kim, Hae‐Ock Lee et al. · 2020 · Experimental & Molecular Medicine
76. A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
    Xiaorui Su, Yuxuan Li, Yupeng Ren, Mingbo Cao, Gaoyuan Yang, Jing Luo, Ziyi Hu, Haixia Deng, Meihai Deng, Bo Liu et al. · 2024 · Biomedicine & Pharmacotherapy
77. No patient left behind: The promise of immune priming with epigenetic agents
    Corey Allan Carter, Bryan T. Oronsky, Joseph Roswarski, Arnold L. Oronsky, Neil C. Oronsky, Jan J. Scicinski, H Lybeck, Michelle M. Kim, Michelle Lybeck, Tony R. Reid · 2017 · OncoImmunology
78. IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients
    Yanwei Liu, Dezhi Gao, Huiyuan Chen, Jing Zhang, Kun Yao, Chenxing Wu, Shouwei Li, Wei Yan, Xiaoguang Qiu · 2023 · Journal of neurosurgery
79. Targeting Wnt signaling in cancer drug resistance: Insights from pre-clinical and clinical research
    Kiavash Hushmandi, Mina Alimohammadi, Mohammad Heiat, Mehrdad Hashemi, Noushin Nabavi, Teimour Tabari, Mehdi Raei, Amir Reza Aref, Najma Farahani, Salman Daneshi et al. · 2025 · Pathology - Research and Practice
80. Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer
    Yapeng Su, Chunmei Liu, Xiang Lu, Guideng Li, Shiqun Shao, Yan Kong, Jihoon William Lee, Rachel H. Ng, Stephanie K. Wong, Lídia Robert et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
81. The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells
    Wayne D. Croft, Rachel Pounds, David N. Jeevan, K. Singh, Janos Balega, Sudha S. Sundar, A. Williams, Raji Ganesan, Sean T Kehoe, Sascha Ott et al. · 2024 · Communications Biology
82. RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
    Corey Allan Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Aiste Degesys, Michelle M. Kim, Arnold L. Oronsky, H Lybeck, Pedro Cabrales, Neil C. Oronsky et al. · 2016 · Case Reports in Oncology
83. Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.
    Tsui-Ting Ho, Xiaolong He, Yin-Yuan Mo, William T. Beck · 2016 · PubMed Central
84. An elementary mathematical modeling of drug resistance in cancer
    Kangbo Bao · 2020 · Mathematical Biosciences & Engineering
85. Jaridon 6, a new diterpene from Rabdosia rubescens (Hemsl.) Hara, can display anti‐gastric cancer resistance by inhibiting SIRT1 and inducing autophagy
    Ling Fu, Bing‐Kai Han, Fangfeng Meng, Jun‐Wei Wang, Tianye Wang, Huiju Li, Ying‐ying Sun, Guo‐na Zou, Xiaorui Li, Wen Li et al. · 2021 · Phytotherapy Research
86. Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method
    Yan Liu, Qelger Bao, Zheng Chen, Lin Yao, Zheng Ci, Xiangyu Wei, Yongjie Wu, Jin Zhu, Kang Sun, Guangdong Zhou et al. · 2021 · Nano Letters
87. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
    Jonas Feldheim, Almuth Friederike Kessler, Julia J. Feldheim, E Schulz, David Wend, Lazaros Lazaridis, Christoph Kleinschnitz, Martin Glas, Ralf‐Ingo Ernestus, Sebastian Brandner et al. · 2022 · International Journal of Molecular Sciences
88. Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy
    Xiaoqiang Sun, Jiajun Zhang, Qi Zhao, Xing Chen, Wenbo Zhu, Guangmei Yan, Tianshou Zhou · 2016 · BMC Systems Biology
89. The Transformation of the Nuclear Nanoarchitecture in Human Field Carcinogenesis
    Greta M. Bauer, Yolanda Stypula‐Cyrus, Hariharan Subramanian, Lusik Cherkezyan, Parvathi Viswanathan, Di Zhang, Ranvir Iyengar, Saurabh Bagalkar, Justin Derbas, Taylor Graff et al. · 2017 · Future Science OA
90. Epigenetically programmed resistance to chemo- and immuno-therapies
    Reddick Russell Walker, Zainab Rentia, Katherine Bakshian Chiappinelli · 2023 · Advances in cancer research
91. Predicting anti-cancer drug combination responses with a temporal cell state network model
    Deepraj Sarmah, Wesley O. Meredith, Ian K. Weber, Madison R. Price, Marc R. Birtwistle · 2023 · PLoS Computational Biology
92. The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy
    Jianmin Wang, Cheng Yang, Huashen Xu, Xinyu Fan, Lina Jia, Yang Du, Shougeng Liu, Wenjing Wang, Jie Zhang, Yu Zhang et al. · 2023 · Advanced Science
93. Combating Multidrug Resistance through an NIR-Triggered Cyanine-Containing Amphiphilic Block Copolymer
    Jia He Tian, Chao Xiao, Baoxuan Huang, Xiaoze Jiang, Hongliang Cao, Feng Liu, Weian Zhang · 2019 · ACS Applied Bio Materials
94. Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies
    Simone Caligola, Francesco De Sanctis, Stefania Canè, Stefano Ugel · 2022 · Frontiers in Genetics
95. Multifunctional core–shell polymeric and hybrid nanoparticles as anticancer nanomedicines
    Katerina Goračinova, Nikola Geškovski, Simona Dimchevska, Xue Li, Ruxandra Gref · 2018 · Elsevier eBooks
96. Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential
    Chenglong Wang, Wencai Guan, Rong Chen, Yael Levi‐Kalisman, Yichun Xu, Liwen Zhang, Min Zhou, Guoxiong Xu, Hongjing Dou · 2020 · Nano Research
97. Drug repurposing of fluoroquinolones as anticancer agents in 2023
    Asmaa E. Kassab, Rania M. Gomaa, Ehab Mohamed Gedawy · 2024 · RSC Advances
98. Protein lactylation and immunotherapy in gliomas: A novel regulatory axis in tumor metabolism (Review)
    Tao Luo, Liang Liu, Hao Wang, Shuai Wen · 2025 · International Journal of Oncology
99. Interplay Between the Histone Variant H2A.Z and the Epigenome in Pancreatic Cancer
    Pedro Antonio Ávila-López, Hober Nelson Núñez-Martínez, Carlos Alberto Peralta‐Álvarez, Santiago Martínez‐Calvillo, Félix Recillas Targa, Rosaura Hernández‐Rivas · 2022 · Archives of Medical Research
100. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers
     Daniel P. Nussbaum, Colin A. Martz, Andrew M. Waters, Alejandro Barrera, Annie Liu, Justine C. Rutter, Christian G. Cerda-Smith, Amy E. Stewart, Chao Wu, Merve Çakır et al. · 2024 · npj Precision Oncology